Pure Global

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS - Trial NCT06392126

Access comprehensive clinical trial information for NCT06392126 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by n-Lorem Foundation and is currently Recruitment Completed. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 1 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06392126
Phase 1/2
Recruitment Completed
drug
Trial Details
ClinicalTrials.gov • NCT06392126
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
An Open-label Study of an Experimental Antisense Oligonucleotide Treatment for a Single Participant With Amyotrophic Lateral Sclerosis (ALS) Due to a Pathogenic Variant in CHCHD10

Study Focus

nL-CHCHD-001

Interventional

drug

Sponsor & Location

n-Lorem Foundation

Jacksonville, United States of America

Timeline & Enrollment

Phase 1/2

Apr 16, 2024

Apr 01, 2025

1 participants

Primary Outcome

Clinical Functioning,Clinical Functioning,Clinical Functioning,Clinical Functioning

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug
 designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a
 pathogenic variant in CHCHD10

ICD-10 Classifications

Neuralgic amyotrophy
Motor neuron disease
Other degenerative diseases of the nervous system
Other degenerative disorders of nervous system in diseases classified elsewhere
Multiple sclerosis

Data Source

ClinicalTrials.gov

NCT06392126

Non-Device Trial